Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  2002-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0009-8981(02)00103-1PMID 12031599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis.

  2001cited by this paper
• C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis

  2001cited by this paper
• Long-term (14 years) effect of LDL apheresis on obstructive changes in aortocoronary saphenous-vein bypass grafts in a case of heterozygous familial hypercholesterolemia with the LDL receptor proline664 to leucine mutation.

  2000cited by this paper
• Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia.

  2000cited by this paper
• Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease.

  1999cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• Clinical efficacy of an automated high-sensitivity C-reactive protein assay.

  1999cited by this paper
• Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis.

  1999cited by this paper
• C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes.

  1999cited by this paper
• Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.

  1998cited by this paper
• Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction.

  1998cited by this paper
• Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

  1998cited by this paper
• Safety and effectiveness of long-term LDL-apheresis in patients at high risk.

  1998cited by this paper
• Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia

  1998cited by this paper
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

  1997cited by this paper
• Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.

  1997cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1997cited by this paper
• Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.

  1995cited by this paper
• Triglyceride‐ and Cholesterol‐Rich Lipoproteins Have a Differential Effect on Mild/Moderate and Severe Lesion Progression as Assessed by Quantitative Coronary Angiography in a Controlled Trial of Lovastatin

  1994cited by this paper
• Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum.

  1994cited by this paper
• Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events

  1993cited by this paper
• Role of oxidised low density lipoprotein in atherogenesis.

  1993cited by this paper
• Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels.

  1993cited by this paper
• Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.

  1992cited by this paper
• Role of oxidized low density lipoprotein in atherogenesis.

  1991cited by this paper
• Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences.

  1991cited by this paper
• Elevation of C-reactive protein in "active" coronary artery disease.

  1990cited by this paper
• The Metabolic basis of inherited disease

  1989cited by this paper
• Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

  1989cited by this paper
• BEYOND CHOLESTEROL, MODIFICATIONS OF LOW-DENSITY LIPOPROTEIN THAT INCREASE ITS ATHEROGENICITY

  1989cited by this paper
• Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits.

  1988cited by this paper
• Transport of beta-very low density lipoproteins and chylomicron remnants by macrophages is mediated by the low density lipoprotein receptor pathway.

  1987cited by this paper
• Causes of death in patients with familial hypercholesterolemia.

  1986cited by this paper
• Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial Hypercholesterolemia

  1985cited by this paper
• Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages.

  1980cited by this paper

• Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)

  2023cites this paper
• Evaluation of vascular quality of life questionnaire in dialysis patients with peripheral arterial disease treated by low-density lipoprotein apheresis

  2016cites this paper
• Beneficial Effect of Endovascular Therapy and Low‐Density Lipoprotein Apheresis Combined Treatment in Hemodialysis Patients With Critical Limb Ischemia due to Below‐Knee Arterial Lesions

  2016cites this paper
• Low-Density Lipoprotein (LDL) Apheresis

  2015cites this paper
• Lipid-Lowering Therapy and Apheresis: Indications and Outcomes

  2015cites this paper
• Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.

  2015cites this paper
• Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design

  2014cites this paper
• Low-Density Lipoprotein Cholesterol: How Low Can We Go?

  2013cites this paper
• Thirty-Six Month Observation of 33 Coronary Vasospastic Angina(VSA) Patients Undergoing a Combination Therapy With a Calcium Channel Antagonist and a Statin : Clinical Evaluation With an Emphasis on the Etiology of Refractory VSA

  2012cites this paper
• A needs assessment and instrument comparison for a therapeutic apheresis medicine service

  2012cites this paper
• Comparison of Different Low Density Lipoprotein Apheresis Machines on Brain Natriuretic Peptide Levels in Patients With Familial Hypercholesterolemia

  2010cites this paper
• Association of ApoE and HDL.C with cardiovascular and cerebrovascular disease: potential benefits of LDL-apheresis therapy

  2009cites this paper
• CHAPTER 30 – Low-Density Lipoprotein Apheresis

  2009cites this paper
• Treatment of Coronary Spastic Angina With a Statin in Addition to a Calcium Channel Blocker: A Pilot Study

  2008cites this paper
• Comparison of different LDL apheresis methods

  2008cites this paper
• Familial Hypercholesterolemia and Lipid Apheresis

  2007cites this paper
• Measures of oxidative stress.

  2006cites this paper
• LDL-apheresis therapy: current therapeutic practice and potential future use

  2006cites this paper
• Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound.

  2005cites this paper
• Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia.

  2004cites this paper
• High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

  2004cites this paper
• Analysis of protein absorbed by LDL column (Liposorber) with special reference to complement component factor D.

  2004cites this paper
• Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge

  2004cites this paper
• Effect of Lipoprotein Apheresis on Oxidative Stress and Antioxidant Status in Familial Hypercholesterolemic Patients

  2004cites this paper
• Indication of Low‐density Lipoprotein Apheresis in Severe Hypercholesterolemia and its Atherosclerotic Vascular Complications: Dextran Sulfate Cellulose Low‐density Lipoprotein Apheresis

  2003cites this paper
• Effect of Lipoprotein Apheresis on Oxidative Stress and Antioxidant Status in Familial Hypercholesterolemic Patients

  2003cites this paper